| Journal: | Revista do Instituto de Medicina Tropical de Sao Paulo |
| Database: | |
| System number: | 000537135 |
| ISSN: | 0036-4665 |
| Authors: | Vianna, Cid Manso de Mello1 Mosegui, Gabriela Bittencourt Gonzalez2 |
| Institutions: | 1Universidade do Estado do Rio de Janeiro, Instituto de Medicina Social, Rio de Janeiro, Rio de Janeiro. Brasil 2Universidade Federal Fluminense, Instituto de Saúde Coletiva, Niterói, Rio de Janeiro. Brasil |
| Year: | 2021 |
| Volumen: | 63 |
| Country: | Brasil |
| Language: | Inglés |
| English abstract | Cryptococcal infection is a frequent cause of mortality in Brazilian HIV-infected patients. The present study aimed to evaluate the cost-effectiveness and budgetary impact of four cryptococcosis screening strategies in HIV-infected patients with CD4+ ≤ 200 cells/mm3, in Brazil. A Monte Carlo microsimulation was used to compare the following diagnostic tests: a systematic serum cryptococcal antigen (CRAG) screening with latex agglutination (CRAG-LA), a lateral flow immunochromatographic test (CRAG-LFA), India ink staining and no intervention. The rationale was that of the Unified Health System (SUS), and the time horizon was of one year for the intervention and of five years for the budgetary impact analysis (BIA). The effectiveness outcomes were years of life and years of life adjusted for quality (QALY). The cost-effectiveness analysis showed that the two cryptococcal antigen tests were cost-effective, presenting with superior results in comparison with India ink and no screening. CRAG-LFA, compared to CRAG-LA, has an incremental cost of US$0.25 and an incremental cost-effectiveness ratio of US$73.36 (considering the US dollar equal to 5 reais, the Brazilian current money). The probabilistic sensitivity analysis between CRAG-LFA and CRAG-LA, despite showing a high agreement between the two tests, indicated the superiority of CRAG-LFA. The BIA estimated that the incorporation of CRAG-LFA would have an additional cost of approximately U$S 10.4 million dollars in five years. These findings suggest that, for the group of studied patients, the adoption of CRAG-LFA and CRAG-LA are cost-effective, while the India ink test and no intervention are less effective strategies. The BIA showed that using the CRAG-LFA test for people living with HIV (PLHIV) with CD4+ ≤ 200 cells/mm3 could reduce costs for the Brazilian Unified Health System (SUS). |
| Keyword: | Cost-benefit analysis, Diagnostic test approval, Cryptococcus, HIV infections |
| Full text: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
